



***In situ* immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system**

Anu Srinivasan^{1,3,4}, Kevin A. Roth^{2,4}, Robert O. Sayers¹,
Kenneth S. Shindler², Angela M. Wong¹, Lawrence C. Fritz¹
and Kevin J. Tomaselli^{1,3}

¹ IDUN Pharmaceuticals, Inc., La Jolla, California and

² Department of Pathology, Washington University School of Medicine,
St. Louis, Missouri, USA

³ corresponding authors: IDUN Pharmaceuticals, Inc. 11085 N. Torrey Pines
Road, Suite 300, La Jolla, California 92037, USA, tel: (619) 623-1330;
fax: (619) 625-2677; e-mail: anu@idun.com, ktomaselli@idun.com

⁴ Contributed equally to this work

Received 5.5.98; revised 20.7.98; accepted 10.8.98

Edited by J.C. Reed

Abstract

Activation of caspase-3 requires proteolytic processing of the inactive zymogen into p18 and p12 subunits. We generated a rabbit polyclonal antiserum, CM1, which recognizes the p18 subunit of cleaved caspase-3 but not the zymogen. CM1 demonstrated an apparent specificity for activated caspase-3 by specifically immunolabeling only apoptotic but not necrotic cortical neurons *in vitro*. In the embryonic mouse nervous system, CM1 immunoreactivity was detected in neurons undergoing programmed cell death and was markedly increased in Bcl-x_L-deficient embryos and decreased in Bax-deficient embryos. CM1 immunoreactivity was absent in the nervous system of caspase-3-deficient mouse embryos and in neurons cultured from caspase-3-deficient mice. Along with neuronal somata, extensive neuritic staining was seen in apoptotic neurons. These studies indicate that caspase-3 is activated during apoptosis in the developing nervous system *in vivo* and that CM1 is a useful reagent for its *in situ* detection.

Keywords: apoptosis; programmed cell death; neuron; caspase-3; immunostaining

Abbreviations: CHAPS: 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid; AcDEVD-amc: N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin; HEPES: N-[2-hydroxymethyl] piperazine-N'-[2-ethanesulfonic acid]; MTS: (3-(4,5-diethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt); PARP: poly ADP-ribose polymerase; TUNEL: terminal deoxynucleotidyl transferase mediated dUTP-nick end labeling

Introduction

Caspases are cysteine proteases that play an important role in the effector phase of programmed cell death or apoptosis (Cohen, 1997; Henkart, 1996). A growing number of caspases

have been identified, of which caspase-3 appears to play a particularly significant role in mediating neuronal apoptosis. For example, caspase-3 is activated in cultured cortical neurons (Keane *et al*, 1997) and cerebellar granule neurons (Armstrong *et al*, 1997) undergoing apoptotic cell death. Moreover, the targeted gene disruption of caspase-3 leads to decreased programmed cell death and results in an expanded ventricular zone, and ectopic and duplicated neuronal structures (Kuida *et al*, 1996). The marked neuronal phenotype resulting from caspase-3 deficiency indicates an important role for caspase-3 in neuronal programmed cell death. However, direct *in situ* evidence for caspase-3 activation during neuronal development has not been reported.

Another family of proteins that regulates neuronal apoptosis in response to a wide variety of signals is encoded by the *bcl-2* gene family (Farlie *et al*, 1995; Frankowski *et al*, 1995; Garcia *et al*, 1992; Gonzalez-Garica *et al*, 1995; Greenlund *et al*, 1995; Martinou *et al*, 1994; Shimizu *et al*, 1995). During nervous system development, Bcl-x_L, an anti-apoptotic member of the Bcl-2 family, and Bax, a pro-apoptotic member regulate immature neuron survival (Shindler *et al*, 1997). The targeted gene disruption of *bcl-x* leads to a massive increase in immature neuron apoptosis while *bax* deletion potentiates neuron survival (Motoyama *et al*, 1995; Roth *et al*, 1996; Deckwerth *et al*, 1996; Shindler *et al*, 1997). The increased death of Bcl-x_L-deficient immature neurons can be prevented both *in vivo* and *in vitro* by concomitant Bax deficiency, indicating that these anti- and pro-apoptotic members of the Bcl-2 family are in critical balance (Shindler *et al*, 1997). While Bcl-2 and Bcl-x_L overexpression have been shown to inhibit caspase activation (Armstrong *et al*, 1996; Chinnaiyan *et al*, 1996; Srinivasan *et al*, 1996), Bax overexpression has been shown to activate caspases (Xiang *et al*, 1996). Thus, the effector caspases appear to function downstream of the Bcl-2 family proteins in a final common pathway of apoptosis.

To investigate this proposed pathway of cell death, it would be useful to be able to detect activated caspases *in situ*. Caspases are expressed in cells as inactive zymogens. Upon induction of apoptosis, the zymogen is activated by proteolytic cleavage at aspartic residues to generate large and small subunits, which together constitute the active enzyme. In the case of caspase-3, the catalytically active form is composed of p18 (amino acids 29–175) and p12 subunits (amino acids 176–277) (Nicholson *et al*, 1995). Cleavage of synthetic caspase-3 substrates and/or endogenous cellular substrates has been used to indirectly monitor caspase-3 activity in cell and tissue extracts (Cohen, 1997). Similarly, detection of downstream apoptotic cellular events (e.g. nuclear condensation and fragmentation, TUNEL and/or ISEL detection of DNA cleavage, annexin V labeling of surface-associated

phosphatidylserine) (Cohen, 1997) or antibodies specific for cleaved substrates of caspases, e.g. Fractin (Yang *et al*, 1998), have been used to indirectly monitor caspase activity *in situ*.

To directly detect activated caspase-3 at the cellular level, we raised a rabbit polyclonal antiserum, CM1, to a 13 amino acid peptide sequence from the carboxyl terminus of the p18 subunit of caspase-3. Characterization of CM1 indicated that it specifically recognized p18 and not the zymogen form of caspase-3 and that it immunolabeled apoptotic but not normal or necrotic neurons *in vitro*. Furthermore, Bcl-x_L deficiency dramatically increased and Bax deficiency decreased neuronal CM1 immunoreactivity in the embryonic mouse nervous system *in vivo*. In apoptotic neurons, CM1 immunoreactivity was present throughout the cell, including neurites. Finally, *in vivo* and *in vitro* studies of caspase-3-deficient neurons demonstrated the specificity of CM1 immunodetection.

Results

CM1 recognizes the large subunit, p18, of processed caspase-3 but not unprocessed zymogen

The reactivity of affinity purified CM1 to processed, recombinant human and mouse caspase-3 was tested by Western analysis. Twenty ng of enzymatically active human caspase-3 and 200 ng of bacterial lysate containing enzymatically active mouse caspase-3 were immunoblotted with CM1 (Figure 1a). As expected, CM1 recognized the large (p18) subunit of recombinant human caspase-3 and several species of the large subunit of recombinant mouse caspase-3. The different mouse caspase-3 large subunits are probably derived from differential proteolysis of the N-terminus during expression in *E. coli*. To determine if CM1 recognizes the unprocessed zymogen form of caspase-3, lysates from control and anti-Fas treated human Jurkat cells were tested for reactivity with CM1 or with a commercially available caspase-3 monoclonal antibody. While the monoclonal antibody clearly recognized the p32 zymogen form of caspase-3 (Figure 1b), CM1 did not. However, CM1 did recognize the large (p18) subunit of processed caspase-3 (Figure 1c). We believe that the caspase-3 large subunit observed in the present study and referred to as p18 is the same CM1 immunoreactive p20 subunit identified in ischemic brain tissue (Namura *et al*, 1998). In addition, in the apoptotic lysates, CM1 also recognized the induction of a strong p30 band and several weaker bands. The identities of these bands are unclear at present (see Discussion), but the p30 band is not pro-caspase-3 (compare electrophoretic mobilities in Figure 1b and c). Thus, in extracts of apoptotic cells known to contain activated caspase-3 (Armstrong *et al*, 1996), CM1 recognized only the processed large subunit (p18) of caspase-3.

CM1 had similar reactivity in murine cortical neurons. Dissociated E15 mouse cortical neurons were cultured for 2 days and treated with 300 μ M cytosine- β -D-arabinofuranoside (AraC) to induce apoptosis. AraC has previously been shown to induce apoptosis in cultured cerebellar granule

neurons (Dessi *et al*, 1995; Ishitani and Chuang, 1996). AraC induced a caspase-3 like protease activity as evidenced by an increase in the cleavage of the synthetic fluorescent tetrapeptide substrate, AcDEVD-amc (Figure 2a) and by cleavage of the endogenous caspase-3 substrate PARP (Figure 2b). Lysates from neurons treated with AraC for various times were analyzed for caspase-3 processing by Western blotting. To demonstrate the recognition of the processed p18 subunit of caspase-3 by CM1 in neurons, CM1 was compared with a polyclonal antibody (CSP3) against recombinant caspase-3, on immunoblots. The caspase-3 monoclonal antibody discussed above could not be used since it does not recognize murine caspase-3. In AraC-treated cultures, CSP3 detected decreased p32 zymogen and induction of processed large (p18) and small (p12) subunits of caspase-3 (Figure 3a). In contrast, CM1 recognized neither the unprocessed p32 or the processed p12 subunit but did immunoreact with the p18 subunit of processed caspase-3 (Figure 3b). The increase in the amount of p18 subunit observed at 4–8 h corresponded to the initial increase in caspase-3-like enzymatic activity. CM1 also recognized several higher molecular weight bands in apoptotic neuronal lysates, similar to those observed in the Jurkat lysates. Interestingly, the cross-reacting proteins accumulated with similar kinetics as the large p18 caspase-3 subunit. Moreover, while the p42 species was weakly recognized by the CSP3 antibody also, the p30 species was not. Additional comparative immunoblots of AraC-treated neuronal lysates using IEF followed by SDS-PAGE with the CSP3 and CM1 antibodies (Figure 3c and d) confirmed that CM1 recognized the processed large subunit of caspase-3. Thus, in cortical neurons induced to undergo apoptosis *in vitro*, CM1 recognized the processed large subunit but not the zymogen form of caspase-3.

CM1 specifically immunostains apoptotic neurons *in vitro*

Since CM1 preferentially recognized processed caspase-3, we compared its ability to label control and apoptotic neurons immunocytochemically. Control or AraC-treated cortical neurons were fixed and subjected to indirect immunofluorescent staining with CM1 (Figure 4a). Control neurons were not labeled by CM1 (Figure 4a, panel C, open arrows). However, apoptotic neurons in cultures treated for 8 or 24 h with AraC stained brightly (Figure 4a, panels F and I, closed arrows). The apoptotic nature of the cells immunostained with CM1 is apparent when the phase contrast image and bisbenzimidazole stained nuclei are compared with corresponding CM1 staining (Figure 4a, panels A–I). CM1 brightly stained both the somata and the neurites of apoptotic neurons. Following 8 h of AraC treatment, neurons could be divided into three classes based on morphology and CM1 immunostaining: (1) cells with normal cellular and nuclear morphology and no CM1 reactivity represented normal cells not yet effected by the AraC-treatment; (2) cells with normal cellular and nuclear morphology but with weak CM1 positivity appeared to represent a population of cells in the early stages of caspase-3 processing and apoptosis (Figure 4a, panel F,




Figure 1 (a) CM1 recognizes the p18 subunit of recombinant mouse and human caspase-3. Twenty ng of recombinant human caspase-3 and 200 ng of bacterial lysate containing recombinant mouse caspase-3 were analyzed by Western blotting for reactivity to CM1. The arrowheads indicate the protein size markers. (b) Caspase-3 monoclonal antibody (Transduction Labs) recognizes the zymogen form of caspase-3 but not the processed forms. Twenty-five μ g each of cell lysates from Jurkat cells treated with anti-Fas for various times were immunoblotted with caspase-3 monoclonal antibody from Transduction Labs. The arrow indicates the unprocessed p32 zymogen form of caspase-3; the arrowheads indicate protein size-markers. (c) CM1 recognizes the processed large subunit of caspase-3 but not the unprocessed zymogen form. Twenty-five μ g each of cell lysates from Jurkat cells treated with anti-Fas for various time points were immunoblotted with CM1. The arrow indicates the processed large subunit (p18) of caspase-3; the arrowheads indicate protein size-markers. The identities of the other CM1 cross-reactive bands are not known

open arrowheads) and (3) neurons which exhibited condensed or marginated nuclei and bright CM1 immunolabeling (Figure 4a, panel F, closed arrows) represented cells undergoing apoptosis.

Following 24 h of AraC treatment, three types of neurons were again found. Some CM1-negative neurons were morphologically normal and thus appeared AraC resistant (Figure 4a, panel I, open arrows). A second group of neurons stained very brightly with CM1 and possessed fragmented or condensed nuclei representative of apoptotic neurons. Occasional neurons with fragmented or condensed nuclei stained either weakly or not at all with CM1 (Figure 4a, panel I, closed arrowhead). In phase contrast, these cells appeared to be in the extreme late stages of apoptotic disintegration. During this phase, cells may have lost most of the caspase-3 subunit recognized by CM1, and therefore showed weak or no CM1 positivity. CM1 immunolabeling of AraC-treated apoptotic neurons (Figure 4b, panel B) was completely abolished by a 50-fold molar excess of CM1 immunogenic peptide but not by a control, unrelated peptide (Figure 4b, panels D and F), demonstrating that the immunolabeling was antigen specific. Control immunostains with purified rabbit IgG,

instead of CM1, showed no labeling of apoptotic neurons (Figure 4b, panel H).

We reported previously that caspase-3 enzymatic activity was not detectable in cerebellar granule neurons following a necrotic insult (Armstrong *et al*, 1997). In order to characterize CM1 immunoreactivity in necrotic neurons, cell lysates were generated from a time course of cortical neurons treated with 1% hydrogen peroxide, harvested at 10 min intervals up to 60 min. As seen with necrotic cerebellar granule neurons, the necrotic cortical lysates did not show any change in caspase-3 enzymatic activity, as measured by AcDEVD-amc cleavage, even at early time points when the cells were not yet propidium iodide (PI) positive (data not shown). Western blotting of these lysates with CM1 did not show induction of any CM1 reactive bands (data not shown). Therefore, to check if CM1 would immunostain necrotic neurons, 2DIV cultures were incubated with medium containing 1% hydrogen peroxide for 1 h. Cells were labeled with PI prior to fixation to identify both necrotic and apoptotic cells that had lost plasma membrane integrity and become PI permeable. CM1 did not label necrotic neurons (Figure 5, indicated by open arrowheads). However, CM1 immunolabeled only the small




Figure 2 (a) AraC induces apoptosis in 2DIV cortical neurons. Time course of loss of cellular viability measured by loss of MTS conversion (open triangles) and the corresponding increase in cleavage of the fluorogenic substrate for caspase-3-like proteases, Ac-DEVD-amc (closed squares) in neurons treated with 300 μ M AraC. (b) AraC induces PARP cleavage in 2DIV cortical neurons. Time course of PARP cleavage in neurons treated with 300 μ M AraC. Open arrows indicate sizes of uncleaved (116 kD) and cleaved (85 kD) PARP

number of neurons in the culture that exhibited apoptotic, fragmented and/or condensed nuclear morphology (Figure 5, indicated by closed arrows).

CM1 selectively immunolabels apoptotic cells *in vivo*

To determine if CM1 labels apoptotic neurons *in vivo*, tissue sections from embryonic mice were immunostained. During embryonic nervous system development, extensive programmed cell death can be seen in both the dorsal root ganglia and spinal cord. Sections from embryonic day 12–15 (E12–E15) mice were double stained with CM1 to detect activated caspase-3 and either a modified TUNEL protocol (to identify nuclei with nicked, apoptotic DNA) and/or bisbenzimidazole to evaluate apoptotic nuclear morphology (condensed, marginated or fragmented). Neurons with apoptotic nuclei were found in the dorsal root ganglia (Figure 6, panel A) and anterior portion of the developing spinal cord (Figure 6, panel D). CM1 immunostaining was readily apparent in these same neuronal structures in the DRG (Figure 6, panels B and C) and the spinal cord (Figure 6, panels E and F).

CM1 immunostaining and TUNEL positivity in the spinal cord occasionally co-localized to individual cells; however, cells with either CM1 or TUNEL reactivity alone were common (compare Figure 6, panels D and E with F). Since

both CM1 immunostaining and TUNEL detection depend on tissue fixation, processing, and signal amplification protocols employed for their visualization, no attempt to quantitate the percentage of colocalization was made. However, 83% of CM1 immunoreactive cells in the embryonic dorsal root ganglia possessed condensed and/or fragmented bisbenzimidazole stained nuclei (199 of 240 CM1 immunoreactive cells counted in sections from 11 E12–E15 mice) indicating that the vast majority of CM1 immunoreactive neurons were apoptotic. Finally, in both the embryonic dorsal root ganglia and spinal cord, intense CM1 immunolabeling of neuritic processes was observed (Figure 6G). In some cases, the processes could be seen to emanate from CM1 positive, apoptotic neuronal cell bodies.

The specificity of CM1 immunostaining was tested on sections from embryonic mice homozygous for a *caspase-3* targeted gene disruption (Kuida *et al*, 1996). If CM1 were specific for activated caspase-3, caspase-3-deficient mice should not have CM1 immunohistochemical reactivity. Sections of wild-type and homozygous caspase-3-deficient E14 mice were immunostained with CM1. CM1 immunoreactivity was found in sections of the wild-type mice (Figure 7A), but was absent in the caspase-3-deficient mouse nervous system, indicating the specificity of CM1 (Figure 7B).

One potential explanation for the ability of CM1 to specifically immunolabel apoptotic cells is that CM1 might be recognizing some apoptosis-related molecule(s) and not activated caspase-3 *per se*. If this were true, CM1 reactivity may be absent in caspase-3-deficient mice since these mice exhibit decreased neuronal apoptosis. This explanation is unlikely for two reasons. Firstly, the number of TUNEL positive dorsal root ganglia cells in caspase-3-deficient E14 embryos decreased only by $54 \pm 13\%$ (mean \pm S.E.M., $n=5$) as compared to wild-type embryos ($n=5$), indicating that, even in the absence of caspase-3, a significant amount of neuronal programmed cell death is ongoing. None of these apoptotic neurons, identified by TUNEL positivity and/or abnormal nuclear features, were stained by CM1. Secondly, numerous apoptotic cells, as evidenced by TUNEL and/or bisbenzimidazole staining, were seen outside the nervous system in the caspase-3 deficient embryos; yet the vast majority of these cells lacked CM1 immunoreactivity (Koth, unpublished observations). Taken together, these data show that CM1 specifically labels activated caspase-3 and not some other apoptosis-related molecule(s) and therefore specifically immunolabels caspase-3-dependent apoptotic neurons *in vivo*.

To further verify the immunocytochemical specificity of CM1, telencephalic cells from *caspase-3*^{+/+} ($n=9$), *caspase-3*^{+/-} ($n=11$), and *caspase-3*^{-/-} ($n=4$) E12–E14 mice were cultured for 48 h in basal medium containing one per cent fetal calf serum which induces low level apoptosis. Unlike telencephalic cultures from wild-type embryos, (Figure 7C), no CM1 immunoreactive cells were observed in the cultures derived from caspase-3-deficient embryos although apoptotic nuclei were readily observed (Figure 7D). Thus, CM1 appears immunospecific for activated caspase-3 both *in vivo* and *in vitro*.




Figure 3 CM1 recognizes the large subunit of processed caspase-3 but not the zymogen. (a,b) Twenty-five μg each of lysates from neurons treated with 300 μM AraC for various times were immunoblotted with CSP3 (a) or CM1 (b). Processing of caspase-3 from the p32 zymogen to the processed subunits p18 and p12 was detected using the CSP3 antibody (a). CM1 recognizes induced p18 subunit which co-migrates with the p18 recognized by CSP3, but not the pro-enzyme p32 form or the p12 subunit (b). Open arrows indicate caspase-3 related bands; closed arrowheads indicate migration of protein size markers. (c,d) Two-dimensional immunoblot analysis of a 16 h apoptotic lysate from neurons treated with 300 μM AraC using CSP3 and CM1. Following IEF and SDS-PAGE, the p18 band is found to be comprised of three proteins, all three of which are recognized by both CSP3 and CM1 (open arrowheads). CSP3 also recognizes the p12 species (closed arrow). Open arrows indicate caspase-3 related proteins; closed arrowheads indicate migration of protein size markers

CM1 immunoreactivity parallels neuronal programmed cell death

To determine if the number of CM1 immunoreactive cells correlated with the level of programmed cell death of neuronal cells in the developing nervous system, CM1 immunoreactivity was examined in wild-type, *bcl-x^{-/-}*, *bax^{-/-}*, and *bcl-x^{-/-}/bax^{-/-}* mice. Bcl-x_L-deficient E12 embryos have been reported to show increased apoptosis in immature neurons (Motoyama *et al*, 1995; Roth *et al*, 1996). Tissue extracts from E12 *bcl-x^{-/-}* brains exhibited significantly higher caspase-3-like proteolytic activity ($260 \pm 29\%$ ($P < 0.05$)) compared with extracts from wild-type E12 brains, as measured by cleavage of the synthetic tetrapeptide substrate AcDEVD-amc. The increased apoptosis in Bcl-x_L-deficient embryos was further evidenced by the intense CM1 immunoreactivity in the anterior horn of the spinal cord and the adjacent dorsal root ganglia in sections from *bcl-x^{-/-}* E12 embryos (Figure 6H).

In order to compare *in vivo* levels of CM1 immunolabeling in a defined population of E12 neuronal cells, the number of CM1 positive cells in the dorsal root ganglia of E12 embryos from wild-type, *bcl-x^{-/-}*, *bax^{-/-}*, and *bcl-x^{-/-}/bax^{-/-}* mice were quantitated (Table 1). As compared to wild-type mice, the number of CM1 positive cells increased approximately twofold in *bcl-x^{-/-}* mice. Consistent with the decreased neuronal apoptosis observed in *bax^{-/-}* mice (Deckwerth *et al*, 1996; Shindler *et al*, 1997), CM1 immunolabeling was virtually abolished in

dorsal root ganglia of *bax^{-/-}* embryos. Bax deficiency has been shown to attenuate the effects of Bcl-x_L deficiency *in vivo* and *in vitro* (Shindler *et al*, 1997). Consistent with this observation, CM1 immunostaining of double deficient mice showed a normalization of CM1 immunolabeling to wild-type levels. Taken together, these data indicate that caspase-3 activation *in vivo* parallels levels of programmed cell death in the developing nervous system.

Lastly, to determine if caspase-3 activation also paralleled levels of *in vitro* neuronal apoptosis in *bcl-x^{-/-}* cells, primary E12 telencephalic cell cultures were prepared from control and Bcl-x_L-deficient mice (Table 2). Compared to wild-type cells (Figure 8A and B), Bcl-x_L-deficient telencephalic cells grown for 48 h in basal medium showed an approximately 2.5-fold increase in apoptotic nuclei (Figure 8C); there was a similar increase in the number of CM1 immunoreactive cells (Figure 8D). These data indicate that caspase-3 activation closely parallels apoptotic neuronal death *in vitro*, as well as *in vivo*.

Discussion

The important role that caspase-3 plays in regulating programmed cell death in the developing nervous system was previously demonstrated in caspase-3-deficient mice (Kuida *et al*, 1996). Although there is variability in the observed neuronal phenotype, caspase-3-deficient mice show a marked reduction in apoptosis in the embryonic nervous system, which results in a variety of structural and




Figure 4 (a) CM1 immunostains apoptotic neurons. Phase contrast and corresponding fluorescence micrographs of control cortical neurons (panels A–C) or neurons treated with 300 μ M AraC for 8 (panels D–F) or 24 h (panels G–I). Open arrows indicate normal cells and nuclei; closed arrows are apoptotic cells and nuclei; open arrowheads identify faintly CM1 immunopositive cells with normal nuclei; closed arrowheads indicate cells with apoptotic nuclei which are negative for CM1. Note that CM1 preferentially immunostains cells which show apoptotic nuclear morphology. (b) CM1 immunostaining of apoptotic neurons is antigen specific. Fluorescence micrographs of cortical neurons treated with 300 μ M AraC for 16 h. Cells were immunostained with control CM1 antibody (panel B), CM1 preincubated with immunogenic peptide (panel D), CM1 preincubated with irrelevant peptide (panel F) or with rabbit IgG (panel H). All cultures were stained with bisbenzimidazole to identify apoptotic cells (panels A, C, E and G). Arrows indicate apoptotic neurons. Note: CM1 immunostaining is abolished by the immunogenic peptide only




Figure 5 CM1 does not label necrotic cells. Phase contrast and fluorescence micrographs of 2DIV neurons incubated in media containing 1% hydrogen peroxide for 1 h. Neurons were incubated with propidium iodide prior to fixation and immunostaining. Note that necrotic cells (open arrowheads) have normal cellular and nuclear morphology. These cells do not stain with CM1. Apoptotic cells exhibit shrunken and fragmented cellular and nuclear morphology (closed arrows) and stain positive with CM1

histopathological abnormalities in the brain. However, the lack of reagents to specifically identify activated caspase-3 *in situ* has limited investigations of caspase-3 activation and its role in experimental and pathological neuronal apoptosis at the cellular level. This study describes the characterization of the CM1 antibody and its application to *in situ* detection of activated caspase-3.

We have previously shown that CM1, by virtue of its enzymatic function-blocking activity (Armstrong *et al*, 1997), can recognize native, enzymatically active caspase-3. In immunoblots of SDS-denatured apoptotic lysates from Fas-treated Jurkat cells and AraC-treated cortical neurons, CM1 recognized the large subunit of processed caspase-3 but not the zymogen form of caspase-3. Thus, in cells CM1 appears to be selective for the activated form of caspase-3.

Regarding the specificity of CM1, in addition to the large subunit of active caspase-3, CM1 also recognized a p30 protein and a few other weaker protein bands that accumulated with kinetics similar to those of the large subunit of caspase-3. This would not be inconsistent with recognition of some other caspases(s), since in most cells multiple caspases become activated during apoptosis (Cohen, 1997). In this regard, CM1 does show weak cross-reactivity to the large subunit of the homologous human protease, caspase-7 (A Srinivasan, unpublished observations). This is not unexpected since 10 of the 13 amino acids in the peptide CM1 immunogen are conserved in caspase-7. However, antibodies to caspase-7 did not detect either caspase-7 or the CM1 cross-reactive proteins in mouse cortical neurons undergoing apoptosis in culture (Srinivasan, unpublished observations). Although recognition by CM1 of these unidentified cross-reactive proteins may contribute to CM1 cellular immunostaining, the absence of CM1 staining in apoptotic neurons from the caspase-3-deficient mice, both *in vivo* and *in vitro*, clearly demonstrates that the cellular CM1 reactivity requires expression and activation of caspase-3.

CM1 immunostaining of cortical neurons induced to undergo apoptosis *in vitro* was largely confined to apoptotic cells. This is consistent with previous reports showing the processing and activation of caspase-3 in cortical neurons following apoptotic signals (Keane *et al*, 1997). The reported lack of caspase-3 activation following a necrotic

insult to cerebellar granule neurons (Armstrong *et al*, 1997) also appears true of cortical neurons as CM1 failed to label necrotic cortical neurons.

A striking observation was the intense CM1 immunolabeling of apoptotic neuronal processes both *in vitro* and *in vivo*. This may not be surprising considering the cytoplasmic distribution of caspase-3 zymogen, the widespread intracellular distribution of mitochondria in neurons, and the important role that cytochrome c efflux from mitochondria appears to play in caspase-3 activation. Recent reports indicate that cytochrome c release into the cytoplasm is an early event in apoptotic signal transduction and can lead to processing and activation of caspase-3 (Yang *et al*, 1997, Kluck *et al*, 1997; Li *et al*, 1997a,b; Bossy-Wetzel *et al*, 1998). Based on the data presented, it is unclear if neuritic caspase-3 activation can occur independently of the neuronal cell body and whether the neuritic CM1 staining observed in apoptotic cortical neurons, embryonic dorsal root ganglia, and embryonic spinal cord reflects an early or late event in apoptosis. Recent studies have indicated that cleaved forms of endogenous caspase substrates are found in neuritic processes associated with amyloid deposition in Alzheimer's disease (Yang *et al*, 1998), suggesting that neuritic activation of caspase-3 may play an important role in neurodegenerative disease.

Activated effector caspases have been shown to function downstream of Bcl-2 family proteins (Armstrong *et al*, 1996; Chinnaiyan *et al*, 1996; Srinivasan *et al*, 1996; Xiang *et al*, 1996). The interplay between the *bcl-2* and *caspase* gene families in regulating programmed cell death was readily observed *in vivo* using CM1 to monitor activated caspase-3 in Bcl-x_L and Bax-deficient mouse embryos. A marked increase in the number of CM1 immunolabeled neurons was observed in the *bcl-x*^{-/-} E12 nervous system while the opposite effect was seen in *bax*^{-/-} embryos. Thus, combined genetic and immunohistochemical evidence indicates that *in vivo* caspase-3 acts downstream of Bcl-x_L and Bax in regulating neuron survival.

The complex, system- and stimulus-dependent role that caspase-3 plays in regulating apoptosis has recently been shown in caspase-3-deficient embryonic stem cells, mouse




Figure 6 CM1 immunolabels neurons undergoing programmed cell death *in vivo*. Fluorescence micrographs of E12 spinal cord (A–C) and dorsal root ganglia (D–F). Apoptotic nuclei in the spinal cord were identified by bisbenzamide staining (panel A) and by CM1 immunolabeling (B). Colocalization of CM1 positivity and fragmented nuclear morphology is shown in the dual exposure micrograph (panel C). The dorsal root ganglia were stained using the TUNEL technique (panel D) and CM1 immunolabeling (panel E). Dual exposure micrographs of these two fields (F) shows some co-localization of TUNEL and CM1 positivity. Arrows (panels A–F) indicate cells wherein the CM1 and nuclear stains colocalized. CM1 immunostaining of the E14 dorsal root ganglia (panel G) shows strong reactivity in both the central and peripheral neuritic projections (indicated by arrows). A cross-section from the upper thoracic region of an E12 *bcl-x*^{-/-} mouse (H) shows nearly confluent CM1 immunoreactivity in the anterior horn of the spinal cord and large numbers of CM1 immunoreactive cells in the adjacent dorsal root ganglia. (Scale bar=25 μ m)




Figure 7 Caspase-3-deficient neurons lack detectable CM1 immunoreactivity. CM1 immunoreactivity is detected in sections of E14 spinal cord from *caspase-3*^{+/+} mice (A) but not in *caspase-3*^{-/-} littermates (B). Sections were lightly counterstained with the nuclear stain hematoxylin. Dual labeling of E14 telencephalic cell cultures with CM1 (green) and bisbenzamide (blue) shows CM1 immunoreactive cells apoptotic cells in cultures from wild-type embryos (C) but not in identical cultures prepared from caspase-3-deficient embryos (D). Closed arrows indicate apoptotic, CM1 positive neurons; open arrows indicate apoptotic cells lacking CM1 immunoreactivity. (Scale bar=25 μ m)

Table 1 CM1 immunoreactivity in E12 DRG

Genotype	CM1 IR cells/field
Wild type	10.6 \pm 3.1
<i>bcl-x</i> ^{-/-}	20.2 \pm 1.8
<i>bax</i> ^{-/-}	0.6 \pm 0.2
<i>bcl-x</i> ^{-/-} / <i>bax</i> ^{-/-}	6.2 \pm 2.6

Sagittal sections of Bouin's fixed, paraffin-embedded E12 mice were immunolabeled with CM1. The number of CM1 immunoreactive (IR) cells per 60 \times magnification field of DRG was counted from a minimum of four DRGs per mouse. Three mice of each genotype were analyzed. The mean \pm standard error of the mean for each genotype was calculated. The difference in number of positive cells per field between any two genotypes was significant ($P \leq 0.05$), except for between wild-type and *bcl-x*^{-/-}/*bax*^{-/-} mice

embryonic fibroblasts, and immune cells (Woo *et al*, 1998). The present studies of the caspase-3-deficient embryonic nervous system indicate that caspase-3 activation is important for some, but not all, apoptotic neuronal death. For example, although programmed cell death is decreased in the dorsal root ganglia of caspase-3-deficient mice, it is not eliminated. Therefore, additional studies are required to define the importance of caspase-3 activation in defined neuronal cell populations and in neuronal apoptosis triggered by different stimuli (e.g. hypoxia, excitotoxicity).

Table 2 Effect of Bcl-x_L deficiency on neuronal apoptosis and caspase-3 activation in vitro

Genotype	% Apoptotic	% CM1 Immunoreactive
<i>bcl-x</i> ^{+/+} (n=10)	30 \pm 7	27 \pm 6
<i>bcl-x</i> ^{-/-} (n=5)	82 \pm 6#	67 \pm 4#

Dissociated E12 telencephalic cells from *bcl-x*^{+/+}, *bcl-x*^{+/-} and *bcl-x*^{-/-} embryos grown for 48 h in unsupplemented basal medium (DMEM) were fixed in 4% paraformaldehyde and then double labeled with CM1 and bisbenzamide. Total cells (labeled nuclei), apoptotic nuclei (condensed and/or fragmented morphology), and CM1 immunoreactive cells were counted. Data represent the mean \pm S.E.M. of the percentage of apoptotic and CM1 immunoreactive cells per embryo. Data from *bcl-x*^{+/+} and *bcl-x*^{+/-} mice were pooled (designated as *bcl-x*^{+/+}) since there were no significant differences between them. #indicates a significant difference between *bcl-x*^{-/-} culture and corresponding *bcl-x*^{+/+} cultures ($P \leq 0.05$)

The data reported here discuss *in vivo* CM1 immunolabeling of apoptotic neurons during embryonic development. However, we have successfully utilized this antibody to study the activation of caspase-3 in neuronal apoptosis induced by external stimuli in adult rats. For example, 24 h post intravenous administration of 1 mg/kg kainic acid to adult rats, CM1 positive apoptotic neurons and neurites were observed in the pyriform cortex. No CM1 positive neurons or neurites were seen in the cortex of vehicle treated rats. Also, the vast majority of CM1 positive cells had abnormal nuclear




Figure 8 E12 telencephalic cell cultures from *bcl-x*^{-/-} mice show increased CM1 reactivity. E12 telencephalic cell cultures from wild-type (A and B), or *bcl-x*^{-/-} mice (C and D) were immunolabeled with CM1 and nuclei were stained with bisbenzamide. Wild-type cultures grown for 48 h in basal medium show occasional cells with apoptotic nuclear morphology (A) with corresponding CM1 immunoreactivity (B). *Bcl-x*_L-deficient telencephalic cultures show a marked increase in cells with apoptotic nuclear morphology (C) which are correspondingly CM1 reactive (D). Arrows indicate apoptotic neurons

features characteristic of apoptosis although occasional CM1 reactive cells with normal appearing nuclei were also found (Srinivasan, unpublished observations). The CM1 antibody has also been used to monitor *in situ* caspase-3 activation in the brain following transient middle cerebral artery occlusion in adult rats (Namura *et al*, 1998, and Srinivasan, unpublished observations).

In summary, our data show that CM1 detects activated caspase-3 or a by-product of caspase-3 activity in neuronal cells undergoing apoptosis. Through the combined use of gene-deficient mice, *in vivo* and *in vitro* experimental systems and the CM1 antibody, we have shown that caspase-3 activation occurs during programmed cell death in the developing nervous system. This antibody should prove to be a valuable tool for evaluating the role of caspase-3 activation during development and in specific pathological and trauma conditions at the cellular level.

Materials and Methods

Animals

Generation of *Bcl-X_L*, *Bax*, and caspase-3-deficient mice by homologous recombination in embryonic stem cells has been described (Motoyama *et al*, 1995; Kuida *et al*, 1996; Shindler *et al*,

1997). Heterozygous (*bcl-x*^{+/-}, *bax*^{+/-}, or *caspase-3*^{+/-}) male and female mice were bred to generate wild-type, heterozygous, and homozygous-deficient embryos, and endogenous and disrupted genes were detected by PCR analysis of tail DNA extracts, as previously described (Shindler *et al*, 1997).

Reagents

Unless otherwise indicated, all media, sera and reagents for tissue culture were purchased from Irvine Scientific, Santa Ana, CA, USA and chemicals, enzymes and protease inhibitors were purchased from Sigma, St. Louis, MO, USA.

Cell culture

Jurkats: Wild-type Jurkats were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 200 Units/ml penicillin, and 200 µg/ml streptomycin. Cell density was always maintained at less than 1×10^6 /ml. **E15 Cortical neurons:** Cortical neurons were isolated from C57Bl/6 mouse embryos (Charles River, Boston, MA, USA) harvested at 15 days of gestation. The cortices from the embryos were isolated in Hank's buffered saline solution (HBSS), freed from meninges, and the tissue was dissociated by digestion in 0.1% trypsin at 37°C for 12 min. The trypsin was inactivated by adding basal media containing 10% FBS and 0.4 mg/ml DNase I, and the tissue was triturated with a 5 ml pipette. Following a 5 min centrifugation at $400 \times g$ at 4°C, the cells were resuspended in a serum-free formulation

of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 2 mM glutamine, 200 Units/ml penicillin, 200 μ g/ml streptomycin, 10 mM HEPES buffer and 1.2 mg/ml bovine serum albumin at 7.5×10^5 cells/ml and plated appropriately in culture plates that were pretreated with polyethylenimine and Minimal Essential Media (MEM) containing 20% FBS (PEI/serum). All culture plates and dishes used were precoated with 0.05% (w/v) PEI dissolved in 0.5 M sodium borate overnight at 37°C. After two washes with phosphate buffered saline (PBS), plates were coated with MEM containing 20% FBS overnight at 37°C. Prior to plating the cortical neurons, plates were washed two times with PBS. All further experimentation with the E15 neurons was done following a two-day *in vitro* (2DIV) culturing at 37°C. **E12 to E14 telencephalic cells:** E12 to E14 telencephalic cells were dissociated as previously described (Shindler and Roth, 1996a). Briefly, pregnant mice were sacrificed between gestational day 12 and 14, embryos removed from the uterus, and separate samples of tail and limb tissue collected from each embryo for DNA extraction. Telencephalic vesicles were isolated, and cells dissociated in a solution of 0.01% trypsin with 0.004% EDTA and 0.001% DNase I, followed by mild trituration with fire-polished Pasteur pipettes. Dissociated cells were washed and resuspended in basal media [a 1:1 mix of DMEM and Ham's F12 Medium (Life Technologies, Grand Island, NY, USA) with 1.2 g/L sodium bicarbonate and 15 mM HEPES, pH 7.4].

Neuronal viability assay

E15 Cortical neurons: Neurons were cultured *in vitro* for two days on PEI/serum coated 96-well culture plates (Costar, Cambridge, MA, USA) at 75 000 cells/well and treated with 300 μ M cytosine- β -D-arabino-furanoside (AraC) for various times. Cells were assayed for viability using the CellTiter Cell Proliferation Assay (Promega, Madison, WI, USA) following manufacturer's instructions. The assay is based upon the reduction of a novel tetrazolium salt, MTS, by respiring cells to a soluble formazan product during a 1 h incubation at 37°C. The amount of soluble product generated is monitored by reading absorbance at 490 nm, corrected for the background reduction by media alone. **E12–E14 telencephalic neurons:** 20 000 cells diluted in 150 μ l of basal media were plated per well on a 48-well tissue culture plate precoated with successive overnight incubations in 0.1 mg/ml poly-L-lysine and 0.01 mg/ml laminin (Collaborative Biomedical Products, Bedford, MA, USA). Cultures were incubated in 5% CO₂ at 37°C for the indicated times. To measure cell viability, 0.04% trypan blue solution was added to unfixed cultures and trypan blue positive and negative cells were counted. Approximately 100 to 200 cells were counted from multiple random fields at 40 \times magnification.

Caspase-3-enzyme assay

In vitro: Neurons cultured in PEI/serum coated in 96-well plates at 75 000 cells/well were treated with 300 μ M AraC for various times. Cells were assayed for caspase-3-like enzymatic activity using a protocol previously described (Armstrong *et al*, 1996). Briefly, following an apoptotic time course, the supernatant medium was carefully aspirated. The cells were lysed by incubation with 50 μ l of hypotonic buffer (10 mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl₂) containing protease inhibitors and 0.1% CHAPS for 10 min (Armstrong *et al*, 1996). One hundred and forty μ l of a buffer containing 20 mM HEPES, pH 7.5, 1 mM EDTA, 5 mM DTT, 10% sucrose and 0.1% CHAPS was added to each well. Caspase-3-like activity was assayed by adding 10 μ l of a 200 μ M AcDEVD-amc (IDUN, La Jolla, CA) stock to the mixture (final substrate concentration=10 μ M). The generation

of the fluorescent aminomethylcoumarin cleavage product was measured on a Cytofluor II fluorescence plate reader (PerSeptive Biosystems, Farmington, CT; excitation=360 nm, emission=460 nm). The enzyme activity is represented as change in amc fluorescence per hour. **In vivo:** Whole brains were isolated from E12 mice, meninges were removed, and brains were placed into 300 μ l cold lysis solution [20 mM HEPES, 1 mM EDTA, and 250 mM sucrose (HES), pH 7.4, containing 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF)]. Tissue was triturated on ice using fire-polished Pasteur pipettes. The concentration of protein in each extract was determined by Lowry assay (Lowry *et al*, 1951) using the Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's protocol. One hundred μ g of each protein sample was diluted into HES solution to a final volume of 135 μ l in individual wells of a 96-well microtiter plate, and control wells were set up containing HES solution alone. Fifteen μ l of a 100 μ M substrate solution containing Ac-DEVD-amc (Biomol Research Laboratories, Plymouth Meeting, PA) was added to each well (10 μ M final concentration). Fluorescent signal was read every 30 min for 1 h on a Titertek Fluoroskan II fluorescent plate reader (excitation=355 nm, emission=460 nm). Additional readings were taken. Duplicate wells were set up for each protein extract, and activity was calculated as the change in mean sample fluorescence minus the mean buffer control fluorescence per hour.

Preparation of apoptotic lysates

To generate apoptotic Jurkat lysates, cells were resuspended at 1×10^6 /ml and treated with 50 ng/ml agonist anti-Fas monoclonal antibody (clone CH-11, Pan Vera Labs, Madison, WI). At various times, cells were harvested by centrifuging at $100 \times g$ for 10 min at 4°C. To generate apoptotic cortical neuron lysates, 2DIV neurons were incubated at 37°C in media containing with 300 μ M AraC. At various times, cells were harvested by gently scraping with a rubber policeman and pelleted at $700 \times g$ for 10 min at 4°C. Cells (5×10^6 cells/time point for Jurkats and 4.4×10^6 cells/time point for neurons) were resuspended in 50 μ l of lysis buffer (50 mM Pipes, pH 7.4, 50 mM KCl, 10 mM EGTA, 2 mM MgCl₂, 1 mM Dithiothreitol (DTT), 0.1 μ M PMSF, 1 μ M Cytochalasin B, 2 μ g/ml Leupeptin, 1 μ g/ml Pepstatin and 10 μ g/ml Aprotinin) and lysed by four successive freeze–thaw cycles at dry ice/37°C. All cell lysates were centrifuged at $12 000 \times g$ at 4°C for 10 min and the clear supernatants were used for Western analysis.

Antibodies

CPP32 monoclonal antibody: A monoclonal antibody to caspase-3 (clone 19) was purchased from Transduction Laboratories (Lexington, KY). **CM1 antibody:** Rabbits were immunized with a 13-amino acid peptide corresponding to the C-terminus of the large subunit of human (amino acid residues 163–175) and mouse caspase-3 (CRGTELDC-GIETD), conjugated to Keyhole Limpet Hemocyanin. **CSP3 antibody:** Rabbits were immunized with recombinant, processed caspase-3 prepared as described below. Full length cDNAs for human and mouse caspase-3 were cloned into pET21b (Novagen, Madison, WI), transformed into *E. Coli* BL 21 (DE3) and expressed as C-terminal 6-His fusion protein. Bacterial cultures grown in LB/ampicillin at 37°C were induced with 1 mM IPTG for 4 h at 25°C and cell pellets were collected by centrifugation for 10 min at $2000 \times g$ at 4°C. Bacterial lysates were prepared by sonicating the pellets in 25 mM TRIS, pH 7.5, 20 mM NaCl, 0.1% Triton X-100, 0.1 mg/ml lysozyme and centrifuging at 4°C ($30 000 \times g$ for 40 min). For antibody production, His-tagged human caspase-3 was purified from bacterial lysate by

nickel chromatography using a hi-trap column (Pharmacia, Piscataway, NJ) and eluted with an imidazole gradient buffer (60 mM–1 M). The protein eluted from the column was found to be fully processed to p18 and p12 subunits. **Antibody purification:** Affinity columns were generated by binding either the free peptide (for CM1) or recombinant caspase-3 (for CSP3) to cross-linked 6% beaded agarose through sulfhydryl groups (Sulfolink Kit, Pierce, Rockford, IL). Columns were incubated with the appropriate immune serum overnight, followed by sequentially washing with 10 mM TRIS, pH 7.4 and a high salt buffer (500 mM NaCl in 10 mM TRIS, pH 7.4). CM1 and CSP3 antibodies were eluted using 100 mM glycine, pH 2.5 (Harlow and Lane, 1988) and buffer exchanged into PBS.

Immunoblotting

Twenty ng of recombinant human caspase-3, 200 ng of bacterial lysate containing mouse caspase-3, and 25 μ g of cell lysates per lane were resolved by SDS–PAGE on 16% TRIS/glycine gels (Novex, La Jolla, CA) and transferred to Immobilon PVDF membranes (Millipore, Bedford, MA). For two dimensional electrophoresis, 80 μ g of the 16 h AraC treated neuronal lysates were subjected to isoelectric focusing (IEF) overnight at 15°C on rehydrated pH 3-10 Immobiline DryStrips (Pharmacia Biotech, Uppsala, Sweden) using a Multiphor II Electrophoresis system (Pharmacia). Following IEF, the samples were resolved in the second dimension by SDS–PAGE, by placing the IEF strips into the sample compartment of precast 16% preparative gels (Novex) and then transferred to Immobilon PVDF membranes. For Western blotting, membranes were blocked in PBS/0.1% Tween (PBST) plus 0.4% casein (I-block, Tropix, Bedford, MA). Blots were incubated with 0.2 μ g/ml primary antibody (anti CPP32 MAb (Transduction Labs, Lexington KY), anti-PARP (Enzyme Systems, Dublin, CA), CM1 or CSP3) diluted in PBST plus casein for 1 h at room temperature. Following three washes with PBST, blots were incubated with 1:15 000 dilutions in PBST plus casein of alkaline-phosphatase conjugated goat anti-rabbit or anti-mouse IgG (Tropix) for 1 h. Following two washes with PBST, blots were washed twice in assay buffer (10 mM diethanolamine, pH 10, 1 mM MgCl₂) and then incubated for 5 min in 250 μ M CSPD chemiluminescent substrate (Tropix) in assay buffer. Blots were wrapped in saran wrap and exposed to Biomax film (Kodak, Rochester, NY) overnight.

Immunostaining

E15 cortical neurons: Neurons were cultured at 2×10^5 cells per chamber on PEI/serum coated 8-well chamber slides (Becton Dickinson, Franklin Lakes, NJ). After 2 days in culture, cells were treated with either 300 μ M AraC for various times (0–24 h) or with 1% hydrogen peroxide for 1 h. Cells were fixed by incubating in 10% formalin in PBS for 20–30 min, washed with PBS and stored at 4°C for up to 24 h. Prior to fixation, the hydrogen peroxide treated cultures were labeled with 1 μ g/ml propidium iodide (PI) for 30 min and gently washed four times with cold PBS to remove excess PI. For immunocytochemistry, fixed cells were blocked for 1 h in PBS containing 10% normal goat serum (NGS), and 0.4% Triton X-100. The cells were then incubated at room temperature for 1 h with CM1 (0.2 μ g/ml) diluted in PBS, containing 2% NGS and 0.4% Triton X-100. Following three washes with PBST, cells were incubated for 1 h with 1 μ g/ml Oregon Green conjugated goat anti-rabbit IgG (Molecular Probes, Portland, OR) and 1 μ g/ml bisbenzimidazole (Hoechst 33258, Sigma) in PBS containing 2% NGS, and 0.4% Triton X-100. Finally, cells were washed four times with PBST and mounted under citifluor (Ted Pella, Redding, CA) with cover slips. Stained cells were visualized under fluorescence on a Nikon Optiphot microscope and

photographed using a Sony CatsEye digital camera. **Peptide competition:** 0.2 μ g/ml of CM1 antibody was preincubated for 1 h at room temperature in PBS, 0.2% NGS, 0.4% Triton X-100 containing a 50-fold molar excess of either the immunogenic peptide (CRGTELDG-GIETD) or an irrelevant peptide (GQVGRQLAIGDDDI). Fixed, apoptotic cortical neurons were immunostained with the preincubated CM1 antibody. For the rabbit IgG control, 0.2 μ g/ml purified rabbit IgG (Pharmingen, San Diego, CA) was used instead of the CM1 antibody. **Mouse embryos and telencephalic cell cultures (in vivo):** Embryonic tissue was obtained, processed, and immunolabeled as previously described (Shindler and Roth, 1996b). Briefly, Bouin's solution (15:5:1 saturated Picric acid:formalin:acetic acid) fixed, paraffin-embedded, 4 μ m thick sections of embryos were used for CM1 immunostaining, TUNEL detection, and multi-label immunohistochemistry. Tyramide signal amplification (TSA) was used to increase the sensitivity of detection over that of conventional techniques. For simultaneous TUNEL and CM1 immunodetection, a modified TUNEL protocol was used as previously described (Tornusciolo et al, 1995). Following deposition of cyanine-3 tyramide (NEN Life Science Products, Boston, MA) to detect TUNEL positive cells, residual peroxidase activity was destroyed by boiling the tissue sections for 1 min in water. 0.5 μ g/ml CM1 antibody, diluted in PBS-blocking buffer (PBS with 1% bovine serum albumin, 0.2% non-fat powdered milk, and 0.3% Triton X-100), was then applied overnight at 4°C and detected using fluorescein tyramide. Tissue was counterstained with bisbenzimidazole (Hoechst 33258) and visualized on a Zeiss-Axioskop microscope equipped with epifluorescence. **Telencephalic cell cultures (in vitro):** CM1 immunocytochemistry was performed using an antibody concentration of 50 ng/ml and TSA with fluorescein-conjugated tyramide detection. Cell nuclei were labeled with bisbenzimidazole as previously described. Numbers of total nuclei, abnormally condensed, fragmented nuclei and CM1 immunoreactive cells were counted from multiple random fields at 40 \times magnification. Approximately 100 to 200 cells were counted per well. Significance was established using one-way ANOVA for cell counts or Kruskal-Wallis ANOVA on percentages of apoptotic or CM1 immunoreactive cells.

Acknowledgements

Caspase-3 deficient mice were generously provided by Drs. Pasko Rakic and Richard Flavell (Yale University). We gratefully acknowledge Drs. Robert Armstrong and Thomas Deckwerth for scientific discussions. We also thank Cecelia Latham and Jacquie McDonough for expert technical assistance and Angela Schroeder for secretarial support. This work was supported in part by NIH grants NS35107 and NS35484.

References

- Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC and Tomaselli KJ (1996) Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. *J. Biol. Chem.* 271: 16850–16855
- Armstrong RC, Aja TJ, Hoang KD, Gaur S, Bai X, Alnemri ES, Litwack G, Karanewsky DS, Fritz LC and Tomaselli KJ (1997) Activation of the CED3/ICE-related protease CPP32 in cerebellar granule neurons undergoing apoptosis but not necrosis. *J. Neurosci.* 17: 553–562
- Bossy-Wetzel E, Newmeyer DD and Green D (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. *EMBO J.* 17: 37–49
- Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG and Dixit VM (1996) Molecular ordering of the cell death pathway. *J. Biol. Chem.* 271: 4573–4576

- Cohen GM (1997) Caspases: the executioners of apoptosis. *Biochem.* 326: 1–16
- Deckwerth TL, Elliott JL, Knudson CM, Johnson Jr EM, Snider WD and Korsmeyer SJ (1996) BAX is required for neuronal death after trophic factor deprivation and during development. *Neuron* 17: 401–411
- Dessi F, Pollard H, Moreau J, Ben-Ari Y, Charriaut-Marlangue C (1995) Cytosine arabinoside induces apoptosis in cerebellar neurons in culture. *J. Neurochem.* 64: 1980–1987
- Farlie PG, Dringen R, Rees SM, Kannourakis G and Bernard O (1995) *bcl-2* transgene expression can protect neurons against developmental and induced cell death. *Proc. Natl. Acad. Sci. USA.* 92: 4397–4401
- Frankowski H, Missotten M, Fernandez P-A, Martinou I, Michel P, Sadoul R and Martinou J-C (1995) Function and expression of the *Bcl-x* gene in the developing and adult nervous system. *NeuroReport* 6: 1917–1921
- Garcia I, Martinou I, Tsujimoto Y and Martinou J-C (1992) Prevention of programmed cell death of sympathetic neurons by the *bcl-2* proto-oncogene. *Science* 258: 302–304
- Gonzalez-Garcia M, Garcia I, Ding L, O'Shea S, Boise LH, Thompson CB and Nunez G (1995) *bcl-x* is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. *Proc. Natl. Acad. Sci. USA.* 92: 4304–4308
- Greenlund LJS, Korsmeyer SJ and Johnson Jr EM (1995) Role of BCL-2 in the survival and function of developing and mature sympathetic neurons. *Neuron* 15: 649–661
- Harlow E and Lane D (1988) *Antibodies: a laboratory manual*, pp 285–317, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- Henkart PA (1996) ICE family proteases: mediators of all apoptotic cell death? *Immunity* 4: 195–201
- Ishitani R and Chuang D-M (1996) Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinoside-induced apoptosis in cultured cerebellar neurons. *Proc. Natl. Acad. Sci. USA.* 93: 9937–9941
- Keane RW, Srinivasan A, Foster LM, Testa M-P, Ord T, Nonner D, Wang H-G, Reed JC, Bredesen DE and Kayalar C (1997) Activation of CPP32 during apoptosis of neurons and astrocytes. *J. Neuroscience Res.* 48: 168–180
- Kluck RM, Bossy-Wetzel E, Green D and Newmeyer DD (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 275: 1132–1136
- Kuida K, Zheng TS, Na S, Kuan C-Y, Yang D, Karasuyama H, Rakic P and Flavell RA (1996) Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. *Nature* 384: 368–372
- Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ and Fritz LC (1997a) Cell-specific induction of apoptosis by microinjection of cytochrome c. *J. Biol. Chem.* 272: 30299–30305
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X (1997b) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91: 479–489
- Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 193: 265–275
- Martinou J-C, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C and Huarte J (1994) Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. *Neuron* 13: 1017–1030
- Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K-I, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S and Loh DY (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. *Science* 267: 1506–1510
- Namura S, Zhu Jinmin, Fink K, Endres M, Srinivasan A, Tomaselli K, Yuan J and Moskowitz MA (1988) Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. *J. Neurosci.* in press
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T, Yu VL and Miller DK (1995) Identification and inhibition of the ICE/Ced-3 protease necessary for mammalian apoptosis. *Science* 376: 37–43
- Roth KA, Motoyama N and Loh DY (1996) Apoptosis of *bcl-x*-deficient telencephalic cells *in vitro*. *J. Neurosci.* 16: 1753–1758
- Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H and Tsujimoto Y (1995) Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. *Nature* 374: 811–813
- Shindler KS, Latham CB and Roth KA (1997) *bax* deficiency prevents the increased cell death of immature neurons in *bcl-x*-deficient mice. *J. Neurosci.* 17: 3112–3119
- Shindler KS and Roth KA (1996a) Cholera toxin binds to differentiating neurons in the developing murine basal ganglia. *Dev. Brain Res.* 92: 199–210
- Shindler KS and Roth KA (1996b) Double immunofluorescent staining using two unconjugated primary antisera raised in the same species. *J. Histochem. Cytochem.* 44: 1331–1335
- Srinivasan A, Foster LM, Testa M-P, Ord T, Keane RW, Bredesen DE, Kayalar C (1996) Bcl-2 expression in neural cell blocks activation of ICE/CED-3 family proteases during apoptosis. *J. Neurosci.* 16: 5654–5660
- Tornusciolo DRZ, Schmidt RE and Roth KA (1995) Simultaneous detection of TDT-mediated dUTP-biotin nick end labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. *BioTechniques* 19: 800–805
- Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW and Mak WM (1998) Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. *Genes Develop.* 12: 806–819
- Xiang J, Chao DT and Korsmeyer SJ (1996) Bax-induced cell death may not require interleukin 1 β -converting enzyme-like proteases. *Proc. Natl. Acad. Sci. USA.* 93: 14559–14563
- Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, Vinters HV, Frautsch SA and Cole GM (1998) Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. *Am. J. Pathol.* 152: 379–389
- Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP and Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. *Science* 275: 1129–1132